Advertisement

Microreactors as New Tools for Drug Discovery and Development

  • S. Y. F. Wong-Hawkes
  • J. C. Matteo
  • B. H. Warrington
  • J. D. White
Conference paper
Part of the Ernst Schering Foundation Symposium Proceedings book series (SCHERING FOUND, volume 2006/3)

Abstract

In common with other producers of fine chemicals, the pharmaceutical industry can deploy flow microreactors to provide a more flexible production regime than is achievable with large-scale batch reactors. With monitoring of output flow, microreactors can be adjusted exquisitely to give enhanced and inherently safer protocols. Bulk production can be achieved through long run times or parallel reactors. However, microreactors can also be used advantageously in pharmaceutical R&D in other ways. This paper describes their use in the creation of a tool for rapid discovery and optimisation of leads to new drugs. Here microreactors are used to create an integrated micro-scaled chemical synthesis and bioassay system able to conduct fast-cycling iterative searches of diverse chemical space as an enhanced method for identifying and optimising novel lead chemotypes. The use of a microreactor to provide point-of-use access to PET ligands is also described. This significant down-scaling and acceleration of the synthesis of potent but short-lived biomarkers of disease could provide a means of significantly shortening the time and resources required to achieve a drug approval.

Keywords

Positron Emission Tomography Market Exclusivity Positron Emission Tomography Probe Positron Emission Tomography Ligand Lead Series 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

References

  1. DiMasi JA, Paquette C (2004) The economics of follow-on drug research and development. Pharmacoeconomics 22(2):1–14CrossRefGoogle Scholar
  2. Garcia-Egido E, Wong SYF, Warrington BH (2002) A Hantzsch synthesis of 2-aminothiazoles performed in a heated microreactor system. Lab Chip 2:31–33CrossRefGoogle Scholar
  3. Garcia-Egido E, Spikmans V, Wong SYF, Warrington BH (2003) Synthesis and analysis of combinatorial libraries performed in an automated micro reactor system. Lab Chip 3:73–76CrossRefGoogle Scholar
  4. Greenway GM, Haswell SJ, Styring P, Morgan DO, Skelton V, Warrington BH, Wong SYF (2001) The generation of concentration gradients using electroosmotic flow in micro reactors allowing stereoselective synthesis. Analyst 126:11–13CrossRefGoogle Scholar
  5. Lipinski CA, Lombardo F, Dominy BW, Feeney PJ (1997) Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. Adv Drug Del Rev 23:3–25CrossRefGoogle Scholar
  6. US Food and Drug Administration (2007) Challenge and opportunity on the critical path to new medical products. http://www.fda.gov/oc/initiatives/criticalpath/whitepaper/html, Cited 6 February 2007Google Scholar
  7. White JD (2003) A dual wavelength optical fluorescence analyser, WO/2003/048744Google Scholar

Copyright information

© Springer-Verlag 2007

Authors and Affiliations

  • S. Y. F. Wong-Hawkes
    • 1
  • J. C. Matteo
    • 2
  • B. H. Warrington
    • 1
  • J. D. White
    • 3
  1. 1.BB Consultants LtdHertfordUK
  2. 2.NanoTek, LLCWallandUSA
  3. 3.Genapta Ltd.CambridgeUK

Personalised recommendations